New IgG4-RD therapeutic avenues, mechanistically driven (B cell-CTL interaction): inebilizumab: registered for NMO, ph3 now obexelimab: novel dual MOA ?safer, ph3 now rilzabrutinib: BTKi, ph2 now elotuzumab: targets SLAMF7, MM registered, NIH study John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS